Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO

Zentalis Pharmaceuticals, Inc.

2023-FY EPS reported -$4.47

Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.
R&D expenses $189.6M (up 9.8%), G&A $64.4M (up 18%) versus FY2022.
Azenosertib Phase 1 monotherapy showed 37% ORR and 6.5-month mPFS in platinum-resistant ovarian/USC cancer patients.
Appointed Diana Hausman, M.D., as CMO and Kyle Rasbach, Ph.D., Pharm.D., as CBO.
NDA submission for azenosertib in gynecologic malignancy targeted for 2026; multiple data readouts in 2024-2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.